2796 Pharmarise Holdings
- 618
- 00.00%
Pharmarise Holdings News
Driven by the weak yen, the consumer spending of tourists visiting Japan in the first 9 months has reached a new high.
①Driven by the weakness of the Japanese yen, Japan's tourism industry is extremely hot in 2024; ②Data shows that as of September, international tourists spent 5.86 trillion yen in Japan (equivalent to 39.27 billion US dollars); ③This exceeded the consumption record of 5.3 trillion yen set for the full year of 2023.
Pharmarise Swings to Loss in Three Months Ended August 31
Pharmarise Holdings Faces Profitability Challenges
September 26th [Today's Investment Strategy]
[FISCO Selected Stock] [Material Stock] Asentec <3565> 581 yen (9/25) Engaged in product development related to virtual desktops. Announced a capital and business alliance with US company CSG, which provides enterprise software solutions. Asentec will allocate 0.7 million shares of common stock to CSG through a third-party allotment (holding ratio after third-party allotment 5.01%). In order to provide higher quality virtual desktop system construction, engineering resources.
Focus on PS and J Oil [Individual stock movements today]
In the U.S. stock market on the 25th, the Dow Jones Industrial Average closed at 41,914.75, down 293.47 points, while the Nasdaq Composite Index rose 7.69 points to 18,082.21. In the Chicago Nikkei 225 futures market, the Osaka day-session price was 320 yen higher at 37,980 yen. The exchange rate was 1 dollar = 144.70-80 yen. In today's Tokyo market, TSI HD <3608> raised its forecast for the first half of the fiscal year ending in February 2025, PS <1871> revised its profit forecast for the fiscal year ending in September 2024, and revised upwards its profit forecast for the first half of the fiscal year ending in March 2025.
Japan oracle corp, 1Q operating profit increased by 20.2% to 22.1 billion yen
Japan's Oracle Corp <4716> announced its performance for the first quarter of the fiscal year ending in May 2025, with revenue increasing by 11.4% year-on-year to 63.915 billion yen, and operating profit increasing by 20.2% to 22.194 billion yen. It achieved record highs in revenue, operating profit, ordinary profit, and net profit for the first quarter. Operating profit exceeded the consensus (approximately 19.6 billion yen). [Positive evaluation] <1871> PS Construction Revised | <4716> Japan Oracle Quarterly <68
Pharmarise Holdings: Summary of financial results for the 1st quarter of the fiscal year ending May 31, 2019 [Japanese GAAP] (consolidated)
Pharmarise 1Q Loss Y131.00M Vs Net Y123.00M
Asahi, Sugi HD (24th)
※The above calendar is a tentative schedule and may be subject to change due to company's convenience. --------------------------------------- September 24th (Tuesday) <3333> Asahi <7649> Sugi HD --------------------------------------- September 25th (Wednesday) <2796> PharmaRise <3160> Daikoh <4465> Niitaka
Pharmarise Holdings: Confirmatory letter.
Pharmarise Holdings: Financial Report - 38th Term (2023/06/01 - 2024/05/31)
Pharmarise Holdings: Extraordinary Report
Pharmarise Holdings: Announcement regarding the dividends of surplus funds.
Pharmarise Holdings Faces Profit Decline, Eyes Recovery
Buy demand next week for Maesawa Chemical Industry and others.
[Buy demand for next week (table)] Code; Stock; Stock price impact; Buy demand; Credit multiplier; Closing price; Previous day comparison <9046>: Kobe Electric Railway; 390%; 35,900; 0.06; 2772; -3 <2796>: Farmalize; 345%; 7,600; 7.09; 635; -2 <3198>: SFP; 315%; 77,900; 0.15; 2163; -5 <8118>: King; 254%; 6,100; 62.03; 755; 0 <9428>: Crops; 20
Pharmarise Holdings To Go Ex-Dividend On May 29th, 2025 With 14 JPY Dividend Per Share
July 2nd (Japan Standard Time) - $Pharmarise Holdings(2796.JP)$ is trading ex-dividend on May 29th, 2025.Shareholders of record on May 31st, 2025 will receive 14 JPY dividend per share. The ex-dividen
Takashimaya revises upwards on February 25, operating profit of 55 billion yen (previously 50 billion yen).
Takashimaya <8233> announced a revision of its financial estimates for the fiscal year ending in February 2025. The operating revenue was revised upward from ¥497 billion to ¥511.4 billion, while the operating profit was revised upward from ¥50 billion to ¥55 billion, reflecting the strong performance of inbound sales in domestic department stores. The first quarter financial results for the February 2025 period showed an operating revenue of ¥120.125 billion, up 13.8% YoY, and an operating profit of ¥17.295 billion, up 56.7% YoY. [Positive rating] Intellix<8940> Revision | <
Pharmarise Holdings: Announcement of differences between financial estimates and actual results for the entire fiscal year of May Heisei 6
Pharmarise Holdings: FY May 2024 financial results announcement (Japan GAAP) (Consolidated)
Pharmarise FY Loss Y351.00M Vs Net Y333.00M
Analysis
Price Target
No Data
No Data